CeeTox Introduces Three New Cardiac Arrhythmia Assessments – Learn More (PDF Download)
CeeTox’s robust, systems-biology approach has developed in vitro models with real predictive power.
We help you identify new drug candidates, chemicals, cosmetics, and consumer products that have the lowest risk for toxicity and the highest probability of success. CeeTox helps you bring safer products to market.
CeeTox recently completed a transaction in which it purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox’ existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings.
Our toxicity screening services can be beneficial for specific industries. These industries include:
Contact CeeTox at firstname.lastname@example.org or 269-353-5555 and find out how our years of experience of in vitro toxicity screening can benefit your company.
On the road with Ceetox
October 23-24, 2013 in Newark, NJ
CeeTox has joined the Smithers Viscent group to provide Endocrine Disruptor Screening Program (EDSP) testing services. Smithers Viscient is comprised of Springborn Smithers, ILS, and CeeTox and provides a one-stop solution to address the full suite of required endocrine disruptor screening tests. The EDSP series of tests were designed to be complementary, and executing the studies as a cohesive unit adds value to the process. The Smithers Viscient group gives its customers the expertise to make informed predictions and evaluate data in real time, saving money and increasing efficiency.
Contact email@example.com for PDF of Genetic Toxicity service offering.